What Labs Do You Need Before Starting Testosterone Therapy?

The lab panel drawn before starting testosterone therapy isn’t a formality — it’s the foundation of safe, effective treatment. Every marker in a pre-TRT workup serves a specific purpose: some confirm the diagnosis, some rule out other causes of the same symptoms, some establish baselines that allow meaningful monitoring, and some screen for conditions that affect whether and how TRT can be safely started.

Most men approaching a TRT evaluation know they need “hormone testing” — but the details of which tests matter, why each is ordered, what the results mean, and how they connect to the treatment decision are rarely explained clearly. This guide covers all of it.

Why the Lab Panel Matters Before You Start

Testosterone therapy is a long-term commitment that affects multiple physiological systems. Getting the pre-treatment labs right has direct clinical implications:

• Confirms the diagnosis — treatment requires biochemically confirmed deficiency, not symptoms alone. Two low morning readings are required under current guidelines.
• Rules out other causes — several conditions (pituitary tumors, thyroid dysfunction, hemochromatosis) produce identical symptoms and need different treatment.
• Establishes critical baselines — hematocrit, PSA, and lipids need pre-treatment readings to meaningfully interpret post-treatment changes.
• Identifies safety concerns — elevated PSA, high hematocrit, or significant cardiovascular abnormalities affect whether and how TRT is initiated.
• Guides protocol selection — LH and FSH levels determine whether primary or secondary hypogonadism is present, which affects delivery method and monitoring decisions.

A physician who prescribes testosterone without a full pre-treatment panel isn’t just cutting corners — they’re creating clinical risk for both patient and provider. For an overview of what the full evaluation process looks like, the first TRT consultation guide covers what a thorough evaluation involves.

The Core Diagnostic Panel: What Confirms the Diagnosis

Current clinical guidelines from the Endocrine Society and the American Urological Association require specific diagnostic steps before testosterone therapy can be appropriately initiated.

Total Testosterone — The Starting Point

Total testosterone is the primary diagnostic marker. The draw must be:

• Fasting — food intake, particularly high-fat meals, can affect readings
• Morning — testosterone peaks between 7–10 AM; afternoon draws can read 20–30% lower in healthy men
• Repeated — guidelines require two separate low readings on two different mornings before diagnosis is confirmed. A single low reading is not sufficient.

General reference: most labs consider below 300 ng/dL deficient, though the clinical threshold is context-dependent and the diagnosis requires symptoms alongside biochemical confirmation.

Free Testosterone + SHBG

Total testosterone measures all testosterone in the blood — but a significant portion is bound to proteins (primarily SHBG — sex hormone-binding globulin) and is biologically inactive. Free testosterone is the unbound fraction that actually enters cells and activates androgen receptors.

Some men have total testosterone readings in the lower-normal range but low free testosterone due to elevated SHBG — meaning their bioavailable testosterone is inadequate despite a seemingly acceptable total number. This is particularly relevant in older men, in whom SHBG tends to rise with age, and in men with liver disease or hyperthyroidism.

SHBG should be measured alongside free testosterone to interpret results correctly. Without SHBG, free testosterone calculated from a formula (rather than directly measured) may be inaccurate.

LH and FSH — Locating the Problem

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are pituitary hormones that signal the testes to produce testosterone and sperm. Their levels tell a physician where the failure is in the HPG axis:

• Low testosterone + high LH/FSH = primary hypogonadism (testicular failure — the pituitary is signaling maximally but the testes can’t respond)
• Low testosterone + low or normal LH/FSH = secondary hypogonadism (pituitary/hypothalamic problem — the signal is inadequate)

This distinction matters for treatment. Secondary hypogonadism may be reversible — weight loss in obese men, addressing sleep apnea, removing a suppressive medication — and may also be approached with alternatives to TRT (clomiphene, hCG) that stimulate natural production. Primary hypogonadism typically requires direct testosterone replacement. LH and FSH cannot be skipped in an initial workup.

Markers That Rule Out Other Causes

Low testosterone symptoms — fatigue, mood changes, reduced libido, cognitive fog, body composition changes — overlap significantly with other treatable conditions. A thorough initial panel screens for these before attributing everything to testosterone deficiency.

TSH + Free T4 (Thyroid)

Hypothyroidism produces fatigue, low mood, cognitive slowing, weight gain, reduced libido, and elevated cholesterol — an almost exact replica of low testosterone symptoms. It’s one of the most commonly missed contributors because it’s not routinely included in basic hormone screening panels.

TSH should be part of every initial TRT evaluation. If TSH is elevated, treating the thyroid dysfunction first (or alongside) may resolve some or all symptoms without needing testosterone replacement — or may significantly change the clinical picture.

Prolactin (Hyperprolactinemia Screen)

Prolactin is listed under the core diagnostic panel because it’s so important, but its role as a rule-out test deserves emphasis. A prolactinoma — the most common pituitary tumor in adults — suppresses LH and FSH, reducing testosterone and causing low libido, erectile dysfunction, and fatigue. It’s entirely treatable with dopamine agonist medications (cabergoline), not testosterone replacement.

A man who presents with low testosterone, low LH, and elevated prolactin needs MRI of the pituitary — not a TRT prescription. Prescribing testosterone in this context treats the downstream effect while missing the underlying cause.

Complete Blood Count (CBC) with Hematocrit

The CBC establishes the pre-treatment baseline for red blood cell production. Hematocrit — the percentage of blood volume occupied by red blood cells — is the most important monitoring marker on TRT because testosterone stimulates erythropoiesis (RBC production). Men who start TRT with borderline-high hematocrit (above 48–50%) require more frequent monitoring and may need protocol adjustments sooner.

A pre-treatment hematocrit also screens for anemia, which can itself cause fatigue and may be a contributing symptom independent of testosterone. For what elevated hematocrit on TRT means and how it’s managed, the high hematocrit guide covers this comprehensively.

Baseline Safety Markers

Several tests establish pre-treatment baselines that are specifically required for monitoring safety once TRT begins. Without a pre-treatment reading, post-treatment changes can’t be meaningfully interpreted.

Table 1 — Pre-TRT baseline safety markers. All establish reference points for monitoring throughout therapy. Without pre-treatment baselines, post-treatment changes cannot be meaningfully attributed to TRT versus pre-existing conditions.

The PSA Question: What Men Need to Know

Prostate-specific antigen (PSA) is among the most important — and most discussed — pre-TRT labs, and it’s worth covering in more detail than a single line in a table.

Current clinical guidelines require a PSA measurement before initiating TRT in men 40 and older. The purpose is not to diagnose prostate cancer — PSA is not a diagnostic test for cancer — but to establish a baseline and screen for values high enough to warrant urological evaluation before starting therapy.

Men with PSA above 4 ng/mL, or with a suspicious pattern on digital rectal exam, are referred to urology before TRT is initiated. Men with active prostate cancer are not candidates for TRT. Men with a history of treated prostate cancer and confirmed remission require individualized evaluation with a urologist.

The concern that TRT causes prostate cancer has been substantially revised in current clinical literature. The current evidence does not support a causal relationship between physiological testosterone replacement and prostate cancer in healthy men. However, PSA monitoring throughout therapy remains standard practice — and the pre-treatment baseline is what makes that monitoring meaningful.

Additional Labs Worth Discussing

Beyond the standard required panel, several additional tests are worth discussing with a physician based on individual history and risk factors.

Iron studies (ferritin, serum iron, TIBC)

Hemochromatosis — hereditary iron overload — is a relatively common genetic condition that deposits iron in the pituitary gland and testes, impairing both LH secretion and testicular testosterone production. It can present as low testosterone with secondary hypogonadism pattern years before being diagnosed. In men with Northern European ancestry, a family history of liver disease, or unexplained hypogonadism, iron studies should be part of the workup.

Bone mineral density (DEXA scan)

Men with longstanding hypogonadism — particularly those whose deficiency went undiagnosed for years — may have measurable bone mineral density loss by the time TRT begins. A baseline DEXA scan provides a starting point for tracking bone density improvement on therapy. This is particularly relevant for men with primary hypogonadism, men over 50, or those with other osteoporosis risk factors.

Sleep study referral (OSA screen)

Obstructive sleep apnea suppresses testosterone by disrupting deep sleep stages during which GH and T are primarily secreted. Men with significant snoring, daytime sleepiness, or witnessed apneas should be screened for OSA before or alongside TRT evaluation — because untreated OSA both explains some low-T symptoms and may be worsened by TRT. Treating OSA first sometimes normalizes testosterone without hormonal intervention.

IGF-1 (Growth Hormone screen)

For men with pituitary pathology or who present with symptoms suggesting both testosterone and growth hormone deficiency — particularly visceral obesity, exercise intolerance, and lipid abnormalities — an IGF-1 level provides a first-line screen for GH axis function. This is relevant when the full picture suggests more than isolated testosterone deficiency. The comparison between TRT and HGH therapy is covered in the HGH vs TRT guide.

Complete Pre-TRT Lab Checklist

Table 2 — Complete pre-TRT lab checklist by priority. “Essential” markers are required for guideline-compliant evaluation. “Important” markers are standard practice. “Situational” markers are ordered based on individual clinical context. For what these labs cost out-of-pocket vs. with insurance, see the TRT cost breakdown.

How to Prepare for Your Lab Draw

What Happens After the Labs

Once the full panel is returned, a physician reviews all results in clinical context — not as individual numbers against reference ranges, but as a constellation of findings that together indicate whether testosterone deficiency is confirmed, what’s causing it, and whether any additional evaluation or referral is needed before initiating therapy.

Several findings may change the immediate course of action:

• Elevated prolactin — MRI of pituitary before any TRT; may indicate prolactinoma
• Low LH with low T — secondary hypogonadism work-up; may reveal reversible cause
• Elevated PSA — urological referral before starting TRT
• Elevated TSH — thyroid treatment may resolve symptoms; reassess T after normalization
• High hematocrit at baseline — more conservative TRT approach; more frequent monitoring
• Only one low T reading — schedule second draw before diagnosis is confirmed

For men whose results confirm straightforward hypogonadism, the path forward leads to the treatment decision — delivery method, dose, and monitoring plan. These steps are covered in the step-by-step TRT guide. For what the ongoing monitoring labs look like once therapy is underway, the TRT side effects and monitoring guide covers the post-treatment surveillance schedule. The relationship between testosterone levels and broader health is explored in the article on baseline testosterone and mortality risk.

Frequently Asked Questions

Can I get a testosterone test without a doctor?

Yes — direct-to-consumer lab services allow you to order a basic testosterone panel (total T, free T, SHBG) without a physician’s order in most U.S. states. This can be useful for preliminary information. However, a physician must still order the full diagnostic panel, interpret results in clinical context, and prescribe treatment. A consumer testosterone test is a starting point, not a complete evaluation — it won’t include prolactin, LH, FSH, PSA, hematocrit, or the other markers needed for safe TRT initiation.

Why do I need the test twice?

Testosterone levels fluctuate based on sleep, stress, illness, recent exercise, and time of day. A single reading — even a low one — may reflect a transient dip rather than true deficiency. Two morning readings on separate occasions establish that the level is consistently below threshold, not just situationally depressed. This requirement prevents overdiagnosis and unnecessary treatment. Up to 30% of men with a single low morning reading have a normal result on a second draw.

What time of day should I get tested?

Between 7 and 10 AM, fasting. Testosterone follows a circadian rhythm, peaking in the early morning and declining substantially through the day. A draw at 2 PM can read 20–30% lower than a morning draw in the same person on the same day — low enough to fall below diagnostic thresholds in men with borderline levels. Afternoon readings are not appropriate for initial diagnostic purposes.

My total testosterone was low — do I need all these other tests?

Yes. A single low total testosterone reading tells you that testosterone is low — it doesn’t tell you why, whether it’s confirmed (one reading is insufficient), whether something else is causing the symptoms, or whether it’s safe to start treatment. Each additional marker in the panel serves a specific purpose that cannot be replaced by testosterone alone. Prolactin and LH/FSH in particular are essential — missing a prolactinoma or misidentifying secondary hypogonadism without checking LH creates real clinical risk.

How much does the pre-TRT lab panel cost?

With insurance and a physician’s order supported by clinical symptoms, much of the panel may be covered after deductible. Out-of-pocket, a comprehensive hormone panel including all markers discussed here typically runs $150–$400 through standard labs. Direct-to-consumer services (LabCorp, Quest, or dedicated hormone testing services) offer panels in the $100–$250 range. For a full cost breakdown including labs, consultations, and ongoing monitoring, see the TRT cost guide.

What if my PSA is slightly elevated?

A mildly elevated PSA (typically 4–10 ng/mL) before TRT initiation typically triggers urological referral for evaluation before proceeding. This may include a free-to-total PSA ratio, repeat PSA testing, or prostate biopsy depending on the clinical picture and urologist recommendation. TRT is not started until prostate pathology has been appropriately evaluated. Active prostate cancer is a contraindication to TRT.

Should I stop any supplements before testing?

Tell your physician about everything you’re taking — prescription medications, OTC medications, supplements, and recreational substances. Don’t stop anything without physician guidance. Products containing DHEA, pregnenolone, or compounds marketed as “testosterone boosters” may affect hormone readings and should be disclosed. The physician decides whether to hold any supplement before testing based on its likely impact on results.

Do I need labs if I already had testosterone testing done elsewhere?

Recent results from an established, certified laboratory — ideally within 3–6 months — may be acceptable to a new physician, particularly for the testosterone readings. However, the physician may still want to repeat specific markers (particularly if timing or fasting status of prior draws is uncertain), order markers not included in a basic consumer panel, or establish baselines in their own system before initiating therapy. Bring all prior lab records to the initial consultation.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229
2. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423–432. doi:10.1016/j.juro.2018.03.115
3. Khera M, Broderick GA, Carson CC, et al. Adult-onset hypogonadism. Mayo Clin Proc. 2016;91(7):908–926. doi:10.1016/j.mayocp.2016.04.022
4. Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317(5):516–524. doi:10.1001/jama.2016.19699
5. Wu FC, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010;363(2):123–135. doi:10.1056/NEJMoa0911101
6. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94(3):907–913. doi:10.1210/jc.2008-1902
7. Leproult R, Van Cauter E. Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA. 2011;305(21):2173–2174. doi:10.1001/jama.2011.710